Literature DB >> 17970884

Dermatologic therapeutics: thalidomide. A practical guide.

M Rosenbach1, Victoria P Werth.   

Abstract

Thalidomide was first introduced in the 1950s, and its widespread use led to thousands of birth defects through the 1960s; it was quickly withdrawn from the market. A fortuitous discovery identified during treatment of patients with erythema nodosum leprosum led to the recognition of the potent anti-inflammatory effects of thalidomide and a resurgence of interest in the drug. In the ensuing decades, thalidomide has been recognized as a potential treatment option in a number of dermatologic conditions. This article reviews the history, pharmacology, mechanisms of action, and off-label uses of thalidomide and serves as a guide for dermatologists to comfortably and safely institute and monitor thalidomide to patients with cutaneous disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17970884     DOI: 10.1111/j.1529-8019.2007.00132.x

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  1 in total

1.  Thalidomide as a Potential HIV Latency Reversal Agent: Is It the Right Time to Forget the Ancestral Sins?

Authors:  Ramachandran Vignesh; Esaki M Shankar
Journal:  EBioMedicine       Date:  2017-08-30       Impact factor: 8.143

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.